News | TCTAP 2022

Was 2021 a bad year for FFR-guided PCI?

William F. Fearon, MD says analysis of FUTURE, FLOWER-MI and FAME 3 trials show FFR-guided PCI still beneficial for select patients with multivessel CAD

May 19, 2022 2683 0 Read More

News | TCTAP 2022

‘CABG helps people live longer’

Cardiac surgeon S. Christopher Malaisrie, MD says CABG improves survival for MVD and LMCAD, despite recent guideline downgrades

May 13, 2022 5135 0 Read More

News | TCTAP 2022

Is CABG the best approach for multivessel, left main CAD?

Mario F.L. Gaudino, MD says PCI and CABG are complementary - not antagonistic – strategies for patients with MVD, LMCAD

May 13, 2022 3314 0 Read More

News | TCTAP 2022

‘Modern trials on SIHD revascularization show no mortality benefit with CABG over medical therapy’

Sripal Bangalore, MD explains 2021 American revasc guidelines sift out old mortality data, throw weight behind contemporary ones

May 12, 2022 9929 0 Read More

News | TCTAP 2022

Tailored de-escalation strategy in PCI and ACS: platelet function test and genetic test guidance

At TCTAP 2022, Dominick J. Angiolillo, MD outlines de-escalation strategies with PFT, genetic tests for PCI-ACS

May 04, 2022 2888 0 Read More

News | TCTAP 2022

Can PCI save lives in severe LV dysfunction?

Divaka Perera, MD says REVIVED-BCIS2 to shed light on revascularization decisions for acute and chronic LV dysfunction

May 04, 2022 3170 0 Read More

News | TCTAP 2022

Real issue in CABG vs PCI for left main? 'Balancing 'hard' outcomes with patient preferences'

Brian Bergmark, MD addresses real-life implications of meta-analysis that showed no mortality difference between PCI-CABG at TCTAP 2022

April 29, 2022 3418 0 Read More